about
Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progressionWhole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer.The molecular basis for ethnic variation and histological subtype differences in prostate cancer.Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer.SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Leading causes of castration-resistant prostate cancer.Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells.FOXA1 inhibits prostate cancer neuroendocrine differentiation.Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4.
P2860
Q28257270-6563C09C-6C68-47D5-A97B-3BBFCFD01D28Q33622362-B857D224-C6EB-4941-B7EB-9D0C6B59FFF4Q33835864-2529DEB7-0226-46B6-97AC-87A590AB4549Q34143112-46685A48-42E7-485E-9FAD-B5F4A92412B9Q36688923-402C69E9-B301-48FF-853A-DA410988D65DQ37564369-2909476C-013E-4C29-BBD8-9F8B010CBE41Q37709535-E40248AF-3502-4117-AFDF-2A4920797DC7Q38341864-7FF83B6C-C9E5-4456-B095-6CA68700E7F8Q38362686-8E77B401-F89F-47E5-990B-C94B16711A52Q38745588-675C89D4-C5AA-4AC8-8A7E-4F5BF5C99D37Q38763212-DDD38F79-E72F-43BA-AB4C-6303CEA86309Q38893882-9F9EA38D-3E37-40E2-AE8B-172D210777B5Q38893994-114EC388-3E8A-4BE2-9D6D-4691F1CA2230Q38923020-4673DBF1-3BA7-480E-94CF-58C757FFEBADQ38930155-AB0CBB2B-F855-42E5-B551-D2933CC357E4Q38952586-9151848E-706E-4DC8-8AC6-9A818A225EC4Q42371512-A5738C03-F75F-4F18-B5C0-1C78B23F23DB
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Neuroendocrine differentiation of prostate cancer.
@en
Neuroendocrine differentiation of prostate cancer.
@nl
type
label
Neuroendocrine differentiation of prostate cancer.
@en
Neuroendocrine differentiation of prostate cancer.
@nl
prefLabel
Neuroendocrine differentiation of prostate cancer.
@en
Neuroendocrine differentiation of prostate cancer.
@nl
P2093
P2860
P356
P1476
Neuroendocrine differentiation of prostate cancer.
@en
P2093
Clark J Chen
Elaine Hsia
Jiaoti Huang
Jill Squires
P2860
P304
P356
10.1038/AJA.2013.7
P577
2013-03-18T00:00:00Z